title: Are serotonergic system genes associated to smoking cessation therapy success in addition to CYP2A6?
abstract: Despite progress made in the treatment of tobacco dependence, currently available treatments are effective for only a fraction of smokers. The aim of this study was to evaluate the association between the effectiveness of treatment with nicotine or bupropion in heavy smokers (n=70), and 6 candidate polymorphisms in CYP2A6, 5-HTT and HTR2A genes. Analysis revealed a significant association between "favourable" genotype combination carriers (CYP2A6 "slow metabolizer" or 5HTT L-allele or HTR2A-1438GG) and nicotine treatment outcome (OR=2.69, 95% CI=1.28-5.64). Genetic variations in CYP2A6 gene or genotypes associated with reduced synaptic serotonin activity may influence the success of smoking cessation treatment.
authors.affiliation: Department of Biomedicine, Universidad Europea de Madrid, Villaviciosa de Odón, Comunidad de Madrid, Spain.
authors.forename: Z
authors.initials: Z
authors.lastname: Verde
authors.affiliation: Department of Biomedicine, Universidad Europea de Madrid, Villaviciosa de Odón, Comunidad de Madrid, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Santiago
authors.affiliation: Department of Neumology, Hospital Gregorio Marañón, Madrid, Comunidad de Madrid, Spain.
authors.forename: J M
authors.initials: JM
authors.lastname: Rodríguez González-Moro
authors.affiliation: Department of Neumology, Hospital Gregorio Marañón, Madrid, Comunidad de Madrid, Spain.
authors.forename: P
authors.initials: P
authors.lastname: de Lucas Ramos
authors.affiliation: Department of Neumology, Hospital Gregorio Marañón, Madrid, Comunidad de Madrid, Spain.
authors.forename: S
authors.initials: S
authors.lastname: López Martín
authors.affiliation: Department of 'Aula de Estudios Avanzados', Fundación Tejerina, Madrid, Comunidad de Madrid, Spain.
authors.forename: F
authors.initials: F
authors.lastname: Bandrés
authors.affiliation: Department of Biomedicine, Universidad Europea de Madrid, Villaviciosa de Odón, Comunidad de Madrid, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Lucia
authors.affiliation: Department of Biomedicine, Universidad Europea de Madrid, Villaviciosa de Odón, Comunidad de Madrid, Spain.
authors.forename: F
authors.initials: F
authors.lastname: Gómez-Gallego
mesh_terms: D000328:Adult; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D016642:Bupropion / Q000627:therapeutic use; D065637:Cytochrome P-450 CYP2A6; D018765:Dopamine Uptake Inhibitors / Q000627:therapeutic use; D005260:Female; D056726:Genetic Association Studies; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009538:Nicotine / Q000627:therapeutic use; D018722:Nicotinic Agonists / Q000627:therapeutic use; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic / Q000235:genetics*; D044402:Receptor, Serotonin, 5-HT2A / Q000235:genetics*; D050486:Serotonin Plasma Membrane Transport Proteins / Q000235:genetics*; D016540:Smoking Cessation; D014029:Tobacco Use Disorder / Q000235:genetics* / Q000628:therapy*
chemical_list: D018765:Dopamine Uptake Inhibitors; D018722:Nicotinic Agonists; D044402:Receptor, Serotonin, 5-HT2A; C493230:SLC6A4 protein, human; D050486:Serotonin Plasma Membrane Transport Proteins; D016642:Bupropion; D009538:Nicotine; D001189:Aryl Hydrocarbon Hydroxylases; C585710:CYP2A6 protein, human; D065637:Cytochrome P-450 CYP2A6